Navigation Links
Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
Date:12/12/2011

al tool for the development and commercialisation of RNAi therapeutics with enhanced efficacy and will continue to work to translate this value into our own RNAi therapeutic pipeline."

Silence Therapeutics is building and strengthening its global, diverse and competitive intellectual property portfolio. This provides the Company and its partners with a strong proprietary position in the RNAi therapeutics space. At present, Silence's global patent portfolio contains issued patents and pending applications covering strategic areas of RNAi therapeutic development. These include multiple proprietary siRNA delivery technologies, potent siRNA sequences specific for high-value disease targets and key RNAi sequence and chemical modifications.

Notes for editors                    

About Silence Therapeutics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry.

The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endo-thelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system e
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
2. Silence Therapeutics Provides Corporate and Development Update
3. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
6. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
7. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
(Date:1/14/2014)... Altadena, CA (PRWEB) January 14, 2014 ... Angeles County), California, and Montreal, Canada, has big ideas ... and non-fiction. The press's goals are to produce high-quality, ... e-books to support local businesses. , The first ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Million Signed in Fourth Quarter, SUNNYVALE, Calif., Aug. ... leader in the field of radiosurgery,announced today financial results ... 2008., For the fourth quarter of fiscal 2008, ... increase over fourth quarter of fiscal 2007,total revenue of ...
... to better emphasize its customer-centric business approach., ... Inc., a,Chicago-area based process and automation engineering firm ... that the company is changing its,corporate identity to ... of Cascade Solutions, "Throughout,our 14 years of serving ...
... system receives Health Canada clearance to treat severe ... vascular dyschromia and wrinkles, MOUNTAIN VIEW, Calif., Aug. ... and market leader of aesthetic,laser skin treatments, today announced ... the recent Health Canada Clearance. The Canadian,debut of the ...
Cached Biology Technology:Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 2Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 3Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 4Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 5Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 6Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 7Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 8Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 9Cascade Controls Changes Corporate Identity to Cascade Solutions 2Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing 2Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing 3Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing 4
(Date:4/17/2014)... drug under clinical trials to treat tuberculosis could be ... act against various bacteria, fungal infections and parasites, yet ... Illinois chemists and collaborators. , Led by U. of ... different ways the drug SQ109 attacks the tuberculosis bacterium, ... pathogens from yeast to malaria and how targeting ...
(Date:4/17/2014)... Information about archaeological remains of ancient chili peppers in ... words for chili peppers in ancient dialects helped researchers ... value of multi-proxy data analysis. Their results are from ... in a special feature issue of the Proceedings ... and animal domestication edited by Dolores Piperno, staff scientist ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Chickens to chili peppers 2Chickens to chili peppers 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2
... Research and a team of collaborators from across the country ... The paper will be published in Nature Genetics ... disease. The gene, dubbed REL, is a member of the ... the body. The NF-B family seems to have a big ...
... on Sustainable Energy Technologies was chosen for multiple reasons: ... climate change, to provide society with security of energy ... For this a European graduate school is thought ... ,school of thought, to foster the development of excellent ...
... and Australian company Stadvis Pty Ltd have signed a ... accurately predicts glycemic index (GI) and resistant starch (RS) ... industry with an accurate means of testing the functional ... that is much quicker and more cost-effective than the ...
Cached Biology News:Researchers identify new risk factor gene for rheumatoid arthritis 2CSIRO deal to commercialize 'artificial gut' 2
... RNA Sample Buffer is a ... for experimental samples and Perfect ... buffer needs no dilution and ... denaturing gels. Simply mix equal ...
... Mouse EL-4 cells were cultured in DMEM and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
... induced prior to DNA purification increasing DNA ... single-copy BACs with the high yields associated ... kits provide the linearized vector and associated ... necessary to create a 10X human BAC ...
... NIH / 3T3 cells were cultured in DMEM ... log phase of growth. In order to ... were fixed in acetone-methanol. The cells are ... slide, with each wells surface specifically treated to ...
Biology Products: